# China NMPA Drug Inspection - Aimin Pharmaceutical Group Co., Ltd. - Yinqiao Detoxification Tablets

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/aimin-pharmaceutical-group-co-ltd/28b1e731-fb8c-434e-8eb7-ced5dfd2ce5b/
Source feed: China

> China NMPA drug inspection for Aimin Pharmaceutical Group Co., Ltd. published April 25, 2022. Drug: Yinqiao Detoxification Tablets. In April 2022, the Beijing Municipal Drug Administration (BMDA) released Announcement No. [2022] 5, detailing results fr

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Beijing Municipal Drug Administration's Announcement on the Second Phase of Drug Quality and Safety Report for 2021
- Company Name: Aimin Pharmaceutical Group Co., Ltd.
- Publication Date: 2022-04-25
- Drug Name: Yinqiao Detoxification Tablets
- Inspection Finding: Content measurement did not meet the requirements
- Action Taken: Relevant authorities have taken necessary control measures against the substandard drugs and are investigating and dealing with the substandard products in accordance with relevant laws and regulations.
- Summary: In April 2022, the Beijing Municipal Drug Administration (BMDA) released Announcement No. [2022] 5, detailing results from the second phase of the 2021 drug quality and safety oversight cycle. Conducted under the 2021 Implementation Plan for Beijing Municipal Drug Quality Sampling and Inspection, the investigation evaluated drug production, distribution, and clinical usage throughout the region. The inspection identified a specific quality violation involving Aimin Pharmaceutical Group Co., Ltd. A batch of their Yinqiao Jiedu Tablets (Batch Number: 1908020), sampled at the Beijing Chang'an Integrated Traditional Chinese and Western Medicine Hospital Co., Ltd., failed to meet mandatory standards. The primary violation was related to content measurement, meaning the active ingredients did not meet the required concentration levels specified in the Chinese Pharmacopoeia 2015 Edition, Part I. Consequently, the BMDA mandated that relevant units implement immediate control measures. These required actions include the sequestration and appropriate legal handling of the non-compliant products to ensure they do not remain in circulation. This enforcement action highlights the administration's commitment to maintaining pharmaceutical safety and regulatory compliance across the supply chain.

Company: https://www.globalkeysolutions.net/companies/aimin-pharmaceutical-group-co-ltd/382353cc-e575-449e-a654-ee2186167b77/